Lantheus Holdings, Inc. $LNTH Shares Sold by Artisan Partners Limited Partnership

Artisan Partners Limited Partnership decreased its position in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 3.3% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 403,994 shares of the medical equipment provider’s stock after selling 13,950 shares during the quarter. Artisan Partners Limited Partnership owned 0.61% of Lantheus worth $20,721,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Elevation Point Wealth Partners LLC acquired a new stake in Lantheus during the 2nd quarter valued at $26,000. Osterweis Capital Management Inc. purchased a new position in Lantheus in the 2nd quarter valued at about $36,000. Hantz Financial Services Inc. boosted its position in Lantheus by 412.5% in the 3rd quarter. Hantz Financial Services Inc. now owns 492 shares of the medical equipment provider’s stock valued at $25,000 after buying an additional 396 shares during the last quarter. First Horizon Corp acquired a new stake in shares of Lantheus during the third quarter valued at about $26,000. Finally, EverSource Wealth Advisors LLC increased its position in shares of Lantheus by 190.2% during the second quarter. EverSource Wealth Advisors LLC now owns 1,065 shares of the medical equipment provider’s stock worth $87,000 after acquiring an additional 698 shares during the last quarter. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Lantheus Trading Down 0.7%

NASDAQ:LNTH opened at $74.91 on Friday. The company has a market cap of $4.97 billion, a PE ratio of 22.23 and a beta of -0.08. The business’s 50 day moving average is $68.15 and its two-hundred day moving average is $60.19. The company has a quick ratio of 2.49, a current ratio of 2.67 and a debt-to-equity ratio of 0.51. Lantheus Holdings, Inc. has a 52 week low of $47.25 and a 52 week high of $111.29.

Lantheus (NASDAQ:LNTH) last posted its quarterly earnings results on Thursday, February 26th. The medical equipment provider reported $1.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.17 by $0.50. Lantheus had a return on equity of 30.37% and a net margin of 15.15%.The business had revenue of $406.79 million for the quarter, compared to analyst estimates of $367.03 million. During the same period in the prior year, the company posted $1.59 EPS. The business’s revenue was up 4.0% compared to the same quarter last year. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. On average, analysts predict that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

Lantheus News Summary

Here are the key news stories impacting Lantheus this week:

• Positive Sentiment: Q4 results: Lantheus reported $1.67 EPS vs. $1.17 expected and revenue of $406.8M vs. $367.0M expected (revenue +4% y/y), showing operational strength and margin improvement. MarketBeat Earnings Report
• Positive Sentiment: Mizuho raised its price target to $85 and set an “outperform” rating, signaling increased analyst conviction and implied upside from current levels. Benzinga
• Positive Sentiment: William Blair upgraded Lantheus from “market perform” to “outperform,” adding another positive analyst endorsement. Street Insider
• Positive Sentiment: Citizens Jmp raised its price target to $78, a modest endorsement that supports the view of upside among some sell‑side analysts. American Banking News
• Neutral Sentiment: JonesTrading reaffirmed a “hold” rating on LNTH, reflecting mixed views on near‑term catalysts. TickerReport
• Neutral Sentiment: Investor materials and transcripts are available (earnings call transcript and presentation), useful for digging into product trends, margin drivers and pipeline commentary. Yahoo Finance Transcript Seeking Alpha Deck
• Negative Sentiment: FY2026 guidance was mixed: EPS guidance of $5.00–$5.25 is roughly in line with consensus (5.16), but revenue guidance of $1.4B–$1.5B leaves room for a slight top‑line miss vs. expectations — a conservative revenue range that could weigh on near‑term sentiment. GlobeNewswire Press Release

Wall Street Analysts Forecast Growth

LNTH has been the subject of a number of analyst reports. Weiss Ratings raised Lantheus from a “sell (d+)” rating to a “hold (c-)” rating in a report on Tuesday, January 6th. Truist Financial set a $89.00 target price on Lantheus in a research report on Friday. JonesTrading cut Lantheus from a “buy” rating to a “hold” rating in a research note on Friday. Citigroup restated an “outperform” rating on shares of Lantheus in a research note on Tuesday. Finally, William Blair raised shares of Lantheus from a “market perform” rating to an “outperform” rating in a report on Thursday. Seven research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Lantheus presently has an average rating of “Moderate Buy” and an average target price of $82.17.

About Lantheus

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.